Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Executive Summary

• Neurothera Labs Inc. disclosed a non‑binding term sheet to acquire a 55% equity interest in a quantum‑computing bio‑data company (“Target Company”).
• The consideration will be issued as common shares equal to 40% of Neurothera’s post‑transaction diluted share capital.
• Completion is subject to due diligence, definitive agreements, regulatory approvals (including TSX Venture Exchange) and customary closing conditions.

Key Details

• Transaction Structure: Non‑binding term sheet for Neurothera to purchase a 55% equity stake in the Target Company on a fully diluted post‑transaction basis.
• Consideration: Issuance of Neurothera common shares representing 40% of the company’s non‑diluted post‑transaction share capital to the selling shareholders.
• Target Business: A pioneering quantum‑computing bio‑data firm focused on “quantum‑enabled clinical analytics,” aiming to accelerate data processing and machine‑learning performance for clinical trials.
• Closing Conditions: Completion requires satisfactory due diligence, negotiation and execution of definitive agreements, receipt of all required corporate and regulatory approvals (including TSX Venture Exchange), and other customary conditions.
• Forward‑Looking Statements: The release contains forward‑looking statements; actual results may differ materially.

Notable Quotes

(No executive quotes were provided in the release.)